Biocon FY24 Annual Earnings Summary
4 quarters covered · ₹14,849 Cr revenue · ₹1,023 Cr PAT · 24.8% average EBITDA margin.
Quarter-by-quarter progression
Management promises made during the year
Promise tracking available after 2+ quarters of coverage.
Risks flagged during the year
USFDA inspections at Malaysia facility resulted in observations; CAPA plans submitted but approval timelines for insulin aspart and bevacizumab remain uncertain.
Q2 FY24 · highFDA issued a CRL for insulin aspart due to pre-approval inspection deficiencies at the Malaysia facility; resolution timeline uncertain.
Q2 FY24 · highMarket adoption of adalimumab biosimilars has been slower than anticipated, impacting Hulio's revenue contribution; management expects improvement only in 2024-25.
Q3 FY24 · highApprovals for Aspart and Bevacizumab are delayed due to FDA's inability to inspect sites, with no clear timeline for resolution, potentially impacting revenue growth and margin expansion.
Q3 FY24 · highBBL net debt stands at $1.2B (excluding structured instruments), with floating-rate SOFR-linked debt exposing the company to high interest costs, which could pressure cash flows and R&D investment.
Q4 FY24 · highBiosimilar adalimumab market in the U.S. is not expected to materially open until calendar 2025, delaying revenue contribution.
Q4 FY24 · highApprovals for biosimilar bevacizumab and insulin aspart depend on FDA inspections of Bengaluru and Malaysia sites, which are pending.
Q1 FY24 · mediumAdalimumab biosimilar uptake has been gradual across the industry; Biocon's Hulio launched July 1, 2023, and payer decisions are still evolving, with meaningful revenue expected only by 2025.
Q1 FY24 · mediumNet debt for Biocon Biologics is over $1.4 billion; depreciation, amortization, and interest increased by INR 353 crore YoY, pressuring net profit.
Q1 FY24 · mediumLegacy rebate contracts caused a $15 million one-off impact on pegfilgrastim; pricing dynamics vary by product and channel, and further rebate adjustments could affect margins.
Q2 FY24 · mediumAPI business faced pricing pressure and muted offtake due to customer inventory stocking; recovery expected but uncertain.
Q2 FY24 · mediumNet debt to EBITDA elevated; interest costs rising due to high rate environment; deferred payments in FY25 may require additional funding.
What changed through the year
Q1 FY24 · Biosimilars core EBITDA margins to return to mid-thirties by end of FY24
Management expects core EBITDA margins for Biocon Biologics to recover to mid-thirties as legacy rebate issues normalize and integration completes.
Q1 FY24 · Generics mid-teen revenue growth for FY24
Generics segment guided for mid-teen revenue growth for the fiscal year, with better second half due to capacity expansions and new product launches.
Q1 FY24 · Generics high double-digit CAGR over 5 years
Generics business expected to grow at 17-20% CAGR over the next 4-5 years, driven by peptides, injectables, and fermentation.
Q1 FY24 · Biocon Biologics CapEx of $150 million for FY24
Capital expenditure for biosimilars business guided at $150 million, primarily for Malaysia expansion and insulin capacity ramp-up.
Q2 FY24 · Biocon Biologics to deliver $1 billion revenue in FY24
Management reaffirmed full-year revenue guidance of $1 billion for Biocon Biologics, driven by market share gains and new product launches.
Q2 FY24 · Syngene mid-teen constant currency growth for FY24
Syngene is expected to deliver mid-teen constant currency growth for the full year, supported by strong performance in development and manufacturing services.
Q2 FY24 · Generics H2 performance to improve over H1
Generics business expects improved second half performance, with formulations steady at ~INR 400 crore per half and API recovery, but full-year growth revised to low teens/high single digit.
Q2 FY24 · Ustekinumab filing on track by end of 2023
Biocon Biologics remains on track to file ustekinumab (Stelara biosimilar) before the end of 2023, with denosumab filing expected by end of next year.
Q3 FY24 · BBL core EBITDA margin target of mid-30s
Management reiterated a mid-30s core EBITDA margin target for Biocon Biologics, with current margins depressed by ~5% due to integration-related one-off costs expected to normalize.
Q3 FY24 · Generics business targeting mid-teens growth next fiscal
Generics business aims to return to mid-teens growth in FY25, driven by formulations momentum and new peptide revenues, despite current API pricing pressure.
Q3 FY24 · Debt reduction focus with $200M repaid in Q3
Management emphasized continued debt reduction, having repaid $200M of acquisition debt in Q3, with further deleveraging expected from cash flows and other options.
Q3 FY24 · Syngene facility operational in H2 FY25
The acquired Stelis biologics facility is expected to be operational in the second half of FY25, subject to regulatory approvals, adding 20,000L capacity.
Q4 FY24 · Syngene FY25 revenue growth: single-digit to low double-digit
Syngene expects constant currency revenue growth of single-digit to low double-digit in FY25.
Q4 FY24 · Syngene FY25 EBITDA margin similar to FY24
Syngene expects operating EBITDA margin to be similar to FY24 levels (~31%).
Q4 FY24 · Biosimilars R&D spend 8%-9% of revenues
Biocon Biologics expects R&D investments to be in the 8%-9% of revenues range.
Q4 FY24 · Generics growth back-ended in FY25
Generics performance expected to build throughout the year with stronger second half, driven by new formulation launches.